GeneDx (NASDAQ:WGS) Director Buys $6,449,850.00 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Keith Meister bought 165,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $39.09 per share, for a total transaction of $6,449,850.00. Following the acquisition, the director directly owned 4,598,297 shares of the company’s stock, valued at approximately $179,747,429.73. This represents a 3.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

GeneDx Stock Performance

Shares of WGS opened at $40.75 on Monday. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -15.21 and a beta of 2.06. The stock has a 50 day moving average of $64.01 and a 200 day moving average of $101.80. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The business had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period in the previous year, the business posted ($0.23) earnings per share. As a group, sell-side analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on WGS shares. Jefferies Financial Group set a $150.00 price target on GeneDx in a research report on Monday, February 23rd. Weiss Ratings raised GeneDx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Wall Street Zen downgraded GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Guggenheim decreased their target price on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Finally, BTIG Research decreased their target price on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Institutional Trading of GeneDx

A number of large investors have recently bought and sold shares of the company. Arizona State Retirement System increased its position in GeneDx by 2.1% in the fourth quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock worth $728,000 after buying an additional 113 shares during the last quarter. Cerity Partners LLC grew its position in shares of GeneDx by 6.0% in the fourth quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock valued at $329,000 after purchasing an additional 142 shares in the last quarter. Main Management ETF Advisors LLC grew its position in shares of GeneDx by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock valued at $2,037,000 after purchasing an additional 160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of GeneDx by 5.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock valued at $399,000 after purchasing an additional 181 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its position in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares in the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Keith A. Meister kept buying shares, including 165,000 shares on May 13, 140,000 shares on May 14, and 46,273 shares on May 15, signaling strong insider confidence in GeneDx’s outlook and helping support the stock. Insider trade filing
• Neutral Sentiment: GeneDx received an average brokerage recommendation of “Moderate Buy,” suggesting Wall Street still sees upside despite the recent volatility. Brokerage recommendation article
• Negative Sentiment: A legal update from Pomerantz LLP said it is investigating claims on behalf of GeneDx investors, adding overhang from possible shareholder litigation after the company’s recent results. Pomerantz investigation article
• Negative Sentiment: Another law firm, Levi & Korsinsky, announced a securities investigation tied to GeneDx’s Q1 revenue miss and reduced full-year guidance, reinforcing concerns that the post-earnings selloff may not be over. Levi & Korsinsky investigation article
• Negative Sentiment: An analyst note cut GeneDx’s price target sharply to $98.94, highlighting a more cautious view after the company’s disappointing quarter. Price target cut article

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.